Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease.

Illnait J, Rodríguez I, Mendoza S, Fernández Y, Mas R, Miranda M, Piñera J, Fernández JC, Mesa M, Fernández L, Carbajal D, Gámez R.

Korean J Intern Med. 2013 Jul;28(4):439-48. doi: 10.3904/kjim.2013.28.4.439. Epub 2013 Jul 1.

2.

Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.

Askari F, Rashidkhani B, Hekmatdoost A.

Nutr Res. 2014 Feb;34(2):143-8. doi: 10.1016/j.nutres.2013.11.005. Epub 2013 Dec 6.

PMID:
24461315
3.

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D.

Gastroenterology. 2013 Sep;145(3):574-82.e1. doi: 10.1053/j.gastro.2013.05.042. Epub 2013 May 30.

PMID:
23727264
4.

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.

Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW.

World J Gastroenterol. 2008 Nov 7;14(41):6395-400.

5.

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group..

Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11.

6.

Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers.

Sesti G, Fiorentino TV, Hribal ML, Sciacqua A, Perticone F.

Nutr Metab Cardiovasc Dis. 2013 Dec;23(12):1182-7. doi: 10.1016/j.numecd.2013.01.006. Epub 2013 Feb 15.

PMID:
23419734
7.

Evaluation of the effect of D-002, a mixture of beeswax alcohols, on osteoarthritis symptoms.

Puente R, Illnait J, Mas R, Carbajal D, Mendoza S, Fernández JC, Mesa M, Gámez R, Reyes P.

Korean J Intern Med. 2014 Mar;29(2):191-202. doi: 10.3904/kjim.2014.29.2.191. Epub 2014 Feb 27.

8.

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.

Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P.

Hepatology. 2008 Jul;48(1):119-28. doi: 10.1002/hep.22336.

PMID:
18537181
9.

Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial.

Magosso E, Ansari MA, Gopalan Y, Shuaib IL, Wong JW, Khan NA, Abu Bakar MR, Ng BH, Yuen KH.

Nutr J. 2013 Dec 27;12(1):166. doi: 10.1186/1475-2891-12-166.

10.

Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents.

de Piano A, de Mello MT, Sanches Pde L, da Silva PL, Campos RM, Carnier J, Corgosinho F, Foschini D, Masquio DL, Tock L, Oyama LM, do Nascimento CM, Tufik S, Dâmaso AR.

Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1313-24.

PMID:
22932160
11.

Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children.

Grønbæk H, Lange A, Birkebæk NH, Holland-Fischer P, Solvig J, Hørlyck A, Kristensen K, Rittig S, Vilstrup H.

J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):223-8. doi: 10.1097/MPG.0b013e31822cdedf.

PMID:
21760546
12.

No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG.

BMC Med. 2016 Jun 29;14:92. doi: 10.1186/s12916-016-0638-y.

13.

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.

Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M; EPE-A Study Group..

Gastroenterology. 2014 Aug;147(2):377-84.e1. doi: 10.1053/j.gastro.2014.04.046. Epub 2014 May 9.

PMID:
24818764
14.

Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.

Panahi Y, Ghamarchehreh ME, Beiraghdar F, Zare R, Jalalian HR, Sahebkar A.

Hepatogastroenterology. 2012 Oct;59(119):2099-2103. doi: 10.5754/hge10860.

PMID:
23234816
15.

Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial.

Lorvand Amiri H, Agah S, Mousavi SN, Hosseini AF, Shidfar F.

Arch Iran Med. 2016 Sep;19(9):631-8. doi: 0161909/AIM.006.

16.

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.

Faghihzadeh F, Adibi P, Hekmatdoost A.

Br J Nutr. 2015 Sep 14;114(5):796-803. doi: 10.1017/S0007114515002433. Epub 2015 Aug 3.

PMID:
26234526
17.

Low 25-hydroxyvitamin D level is associated with insulin sensitivity in obese adolescents with non-alcoholic fatty liver disease.

Pirgon O, Cekmez F, Bilgin H, Eren E, Dundar B.

Obes Res Clin Pract. 2013 Jul-Aug;7(4):e275-83. doi: 10.1016/j.orcp.2012.01.004.

PMID:
24306155
18.

A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease.

Zhang PW, Chen FX, Li D, Ling WH, Guo HH.

Medicine (Baltimore). 2015 May;94(20):e758. doi: 10.1097/MD.0000000000000758.

19.

Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.

Farhangi MA, Alipour B, Jafarvand E, Khoshbaten M.

Arch Med Res. 2014 Oct;45(7):589-95. doi: 10.1016/j.arcmed.2014.11.001. Epub 2014 Nov 11.

PMID:
25450583
20.

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.

Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A.

Nutr Res. 2014 Oct;34(10):837-43. doi: 10.1016/j.nutres.2014.09.005. Epub 2014 Sep 23.

PMID:
25311610

Supplemental Content

Support Center